Proline dehydrogenase (PRODH) is a mitochondrial enzyme involved in proline catabolism and has been implicated in metabolic reprogramming of cancer cells. The source study notes that currently available PRODH inhibitors have limited scaffold diversity, motivating the search for novel chemical scaffolds that can modulate PRODH activity and downstream metabolic and transcriptional programs relevant to tumor biology.
Using a combination of virtual screening and experimental binding assays, the investigators identified a compound designated MBTP-15324 as a candidate PRODH allosteric inhibitor. In a PRODH-GFP binding system measured by microscale thermophoresis, MBTP-15324 demonstrated a low-micromolar dissociation constant (Kd = 1.45 μM), indicating measurable affinity for PRODH under the assay conditions reported in the source.
The source frames MBTP-15324 as a novel-scaffold chemical starting point rather than a finalized therapeutic, reflecting its role in early-stage inhibitor discovery.
Molecular dynamics simulations were used to evaluate the stability of MBTP-15324 within the predicted allosteric pocket of PRODH (referred to as Cavity1 in the source). Simulation data reported in the abstract and plain-language summary supported stable binding of MBTP-15324 in the predicted pocket, consistent with the experimentally determined low-micromolar binding affinity. The source emphasizes that these data together support MBTP-15324 as a putative allosteric inhibitor rather than an orthosteric active-site ligand.
Cell-based assays in PRODH-overexpressing lung cancer cell models demonstrated that MBTP-15324 reduced several malignant phenotypes. Specifically, in the human A549 and murine LLC cell lines engineered or described as PRODH-overexpressing, MBTP-15324 significantly attenuated:
The source indicates a preferential effect in PRODH-overexpressing contexts, suggesting that cellular PRODH expression may influence sensitivity to MBTP-15324. Details such as concentrations tested, exposure durations, quantitative effect sizes, and statistical metrics were not reported in the available abstract and plain-language summary.
The investigators applied multi-omics analyses to profile the biochemical and transcriptional consequences of MBTP-15324 treatment. According to the source, MBTP-15324 "partially reversed arginine-proline metabolic dysregulation" observed in the studied lung cancer cells. This indicates that treatment affected metabolites or fluxes within the arginine–proline axis, consistent with inhibition of PRODH activity.
The abstract and plain-language summary do not provide detailed metabolite names, fold changes, or pathway-enrichment statistics; those experimental specifics were not reported in the source material provided.
Transcriptome-level analyses described in the source revealed that MBTP-15324 treatment downregulated transcriptional programs associated with:
These gene-expression changes align with the observed reductions in migration and colony formation and suggest that PRODH inhibition with MBTP-15324 can influence both metabolic and non-metabolic (e.g., adhesion and ECM-related) components of tumor cell phenotype.
Specific gene lists, pathway enrichment p-values, or sample sizes for transcriptomic experiments were not reported in the abstract and plain-language summary.
The authors conclude that MBTP-15324 is a promising novel-scaffold candidate PRODH allosteric inhibitor that influences proline-related metabolism and ECM-associated gene-expression programs in lung cancer cells. They propose MBTP-15324 as a chemical starting point for future PRODH-targeted therapies and metabolic interventions in lung cancer.
Limitations and gaps noted from the source material:
Overall, MBTP-15324 is presented in this source as an early-stage, mechanistically supported candidate inhibitor of PRODH with both biochemical binding evidence and cellular phenotypic effects in PRODH-overexpressing lung cancer models. Further work would be required to expand on dosing, specificity, off-target profiling, detailed mechanism of allosteric modulation, and in vivo efficacy and safety; those data were not reported in the provided abstract and plain-language summary.